The California-based biotech priced its shares at $18. Its lead product, a weight loss treatment called Azelaprag, is still ...
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback